Pramipexole in depression - a follow-up study
Key facts
- Where
- Malmö, SvédországSee the site
- Phase
- 3. fázis
Where in Svédország
- Region SkåneMalmö, SvédországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Skane
- Trial code
- EU 2022-502270-17-00
- Record updated
- 2025. április 22.
- Original description
To investigate efficacy and tolerability of long-term add-on pramipexole in anhedonic depressionRead full original descriptionShow less
Long-term efficacy and tolerability of add-on pramipexole for anhedonic depression – an open label follow-up study
To investigate efficacy and tolerability of long-term add-on pramipexole in anhedonic depression
Inclusion: Previous participation in RCT testing the short-term efficacy of pramipexole vs placebo (EudraCT# 2022-001563-26); Study participants randomized to pramipexole in the RCT who wish to continue with their treatment can enrol in the study; Study participants randomized to placebo in the RCT who fulfil the inclusion criteria after the RCT can enrol in the study; The research subject has given informed consent to participate in the study; Additional inclusion criterion for patients receiving placebo during the RCT: Anhedonia symptoms: 3 or 4 points on ≥ 3 items of the Snaith-Hamilton Pleasure Scale (SHAPS-C). This has been adopted in previous studies as a definition of "clinically significant anhedonia"27.
Exclusion: Other medical conditions or other concomitant drug treatment (see section 13.5) which, in the opinion of the investigators, may affect the evaluability of the trial or conditions that increase trial risk. For example, Parkinson's disease, hepatic insufficiency, ongoing cancer not in remission for more than one year, older bariatric surgery with a known impact on absorption of extended-release tablets; Known or suspected allergy to any active substance or excipient in the medicinal product included in the trial; Known diagnosis of Emotionally Unstable Personality Disorder; History of or a strong clinical suspicion of impulse control disorder (including current binge-eating disorder) or a current ADHD diagnosis with hyperactivity; Diagnosis of intellectual disability, dementia, or other circumstance that makes it difficult to understand the meaning of participating in the trial and give informed consent; Diagnosis of renal failure (eGFR < 50 ml/min/1.73m2) or severe cardiovascular disease (specifically symptomatic heart failure NYHA Class II or higher). Blood samples from RCT are sufficient to rule this out; Pregnancy, breastfeeding or planned pregnancy (if female); Recently started psychotherapy (within 6 weeks); Ongoing or planned ECT, ketamine or rTMS treatment, excluding maintenance ECT, ketamine or rTMS. (Maintenance treatment is defined as the use of ECT/ketamine/rTMS for a period exceeding 3 months after a series of ECT/ketamine/rTMS treatment in order to prevent the onset of a new episode); Participation in other treatment studies; Other reason, as assessed by the investigator, that prevents the research subject's participation, such as the risk that the research subject is unable to complete the trial (non-compliance); High suicide risk according to the overall clinical assessment of the research physician; Ongoing substance abuse (within 6 months); Diagnosis of current psychosis; Treatment under LPT.